1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Sclc: new trials by email Literature Review of Sclc trials Research Report on Sclc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
Carcinoma, Small Cell (1) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Carboplatin (1) · EC regimen (1) · Etoposide (1) · PM 01183 (1) · atezolizumab (1)
SystImmune Inc. (1)
Australia (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Serbia (1) · Spain (1) · United States (1)
Junliang Cai, MD (1)